Site icon pharmaceutical daily

Achondroplasia Pipeline Review, H2 2020: 7 Companies & 7 Drug Profiles – Therapeutics Assessment, Competitive Landscape, Drug Profiles, Dormant Projects, Product Milestones – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Achondroplasia – Pipeline Review, H2 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Achondroplasia – Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Achondroplasia (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Achondroplasia (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Achondroplasia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 2, 1 and 1 respectively.

Achondroplasia (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Reasons to Buy

Key Topics Covered:

Introduction

Achondroplasia – Overview

Achondroplasia – Therapeutics Development

Achondroplasia – Therapeutics Assessment

Achondroplasia – Companies Involved in Therapeutics Development

Achondroplasia – Drug Profiles

ACP-015 – Drug Profile

Aptamer for Achondroplasia – Drug Profile

Fusion Protein to Agonize NPR2 for Achondroplasia – Drug Profile

infigratinib phosphate – Drug Profile

RBM-007 – Drug Profile

TA-46 – Drug Profile

vosoritide – Drug Profile

Achondroplasia – Dormant Projects

Achondroplasia – Product Development Milestones

Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/le7m6q

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Exit mobile version